{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:36:15Z","timestamp":1764102975969,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009954","name":"Taiho Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009954","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010795","name":"Chugai Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010795","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008728","name":"Japan Research Foundation for Clinical Pharmacology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.clgc.2018.09.015","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T23:44:50Z","timestamp":1538178290000},"page":"e1-e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration\u2013Time Curve for Metastatic Renal-Cell Carcinoma"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-628X","authenticated-orcid":false,"given":"Yuji","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiyo K.","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9203-4245","authenticated-orcid":false,"given":"Nobuaki","family":"Matsubara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Shinojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1991-4166","authenticated-orcid":false,"given":"Fumiya","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Tanigawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2018.09.015_bib1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s40262-013-0068-3","article-title":"Clinical pharmacology of axitinib","volume":"52","author":"Chen","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clgc.2018.09.015_bib2","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2018.09.015_bib3","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1200\/JCO.2005.04.192","article-title":"Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results","volume":"23","author":"Rugo","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcph.73","article-title":"Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis","volume":"53","author":"Rini","year":"2013","journal-title":"J\u00a0Clin Pharmacol"},{"year":"2012","series-title":"Inlyta (axitinib) tablets for oral administration","author":"US Food and Drug Administration","key":"10.1016\/j.clgc.2018.09.015_bib5"},{"key":"10.1016\/j.clgc.2018.09.015_bib6","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1349-7006.2009.01465.x","article-title":"Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients","volume":"101","author":"Mukohara","year":"2010","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clgc.2018.09.015_bib7","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1016\/j.jchromb.2009.10.024","article-title":"Liquid chromatography\u2013tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma","volume":"877","author":"Sparidans","year":"2009","journal-title":"J\u00a0Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.clgc.2018.09.015_bib8","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin Chim Acta"},{"year":"2001","series-title":"Guidance for industry. Bioanalytical method validation","key":"10.1016\/j.clgc.2018.09.015_bib9"},{"key":"10.1016\/j.clgc.2018.09.015_bib10","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","article-title":"Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma","volume":"22","author":"Motzer","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib12","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/annonc\/mdv103","article-title":"Axitinib dose titration: analyses of exposure, blood pressure and clinical response from a randomized phase\u00a0II study in metastatic renal cell carcinoma","volume":"26","author":"Rini","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00280-009-1170-y","article-title":"Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic\/pharmacodynamic meta-analysis","volume":"66","author":"Houk","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.clgc.2018.09.015_bib14","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2018.09.015_bib15","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib16","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyt054","article-title":"Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized phase 3 AXIS trial","volume":"43","author":"Ueda","year":"2013","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.clgc.2018.09.015_bib17","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2011.07.014","article-title":"Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell carcinoma","volume":"47","author":"Tomita","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2018.09.015_bib18","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.ejca.2014.02.007","article-title":"Controversies in renal cell carcinoma: treatment choice after progression on vascular endothelial growth factor\u2013targeted therapy","volume":"50","author":"Calvo","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300405?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767318300405?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:17Z","timestamp":1761564737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767318300405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1558767318300405"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.015","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Individualized Dosing of Axitinib Based on First-Dose Area Under the Concentration\u2013Time Curve for Metastatic Renal-Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2018.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}